MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Abroad (travel likely)RecruitingPHASE2

Conditions

NSCLC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Zhengzhou University,, Zhengzhou, Henan, China
Contact: Study coordinator (Feng Li, MD) · LF_0604@163.com · +8615838222689

Study leads

Yu Qi
Principal Investigator
The First Affiliated Hospital of Zhengzhou University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

NSCLC (Advanced Non-small Cell Lung Cancer) · EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE2

Rochester, United States · Toronto, Canada

Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

EGFR Mutation-positive NSCLC

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Shandong, China

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Gilbert, United States · Phoenix, United States